KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) 10-Year Financial Performance & Capital Metrics

KMTS • • Industrial / General

HealthcareMedical InstrumentsDiagnostic & Monitoring EquipmentDiagnostic Testing & Monitoring

AboutKestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its Cardiac Recovery System platform is the ASSURE WCD, a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). The company's Cardiac Recovery System platform also includes a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.Show more

Revenue $60M +115.1%
EBITDA -$98M -33.9%
Net Income -$114M -20.9%
EPS (Diluted) -5.13 -151.5%
Gross Margin 40.47% +3009.9%
EBITDA Margin -164.52% +37.7%
Operating Margin -177.84% +41.8%
Net Margin -190.28% +43.8%
ROE -55.41%
ROIC -658.17%
Debt/Equity 0.22
Interest Coverage -13.75 -0.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-567.83%

5Y Avg-567.83%

3Y Avg-614.47%

Latest-78.58%

Peer Comparison

Diagnostic Testing & Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NNNNAnbio Biotechnology Class A Ordinary Shares	1.8B	41.11	734.11	21.95%	31.03%	29.08%	0.12%
DXRDaxor Corporation	69.94M	13.88	126.18	-93.84%	401.5%	9.78%	0.04%	0.02
BDXBecton, Dickinson and Company	57.41B	201.52	34.57	8.23%	7.68%	6.61%	4.65%	0.76
HOLXHologic, Inc.	16.7B	74.87	22.55	-0%	13.79%	11.5%	6.86%	0.52
GCTKGlucoTrack, Inc.	3.31M	3.64	0.06			-389.1%
QDELQuidelOrtho Corporation	2.26B	33.30	-1.09	-7.17%	-43.43%	-57.92%		0.90
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.	1.29B	22.04	-4.30	115.05%	-177.99%	-80.55%		0.22
OSUROraSure Technologies, Inc.	186.51M	2.60	-10	-54.17%	-47.92%	-16.64%	12.64%	0.04

Profit & Loss

	Apr 2020	Apr 2021	Apr 2023	Apr 2024	Apr 2025
Sales/Revenue+	0	0	7.63M	27.81M	59.81M
Revenue Growth %	-	-	-	2.65%	1.15%
Cost of Goods Sold+	0	0	18.28M	27.45M	35.6M
COGS % of Revenue	-	-	2.4%	0.99%	0.6%
Gross Profit+	0	0	-10.65M	362K	24.21M
Gross Margin %	-	-	-1.4%	0.01%	0.4%
Gross Profit Growth %	-	-	-	1.03%	65.88%
Operating Expenses+	29.32M	32.71M	69.77M	85.42M	130.59M
OpEx % of Revenue	-	-	9.14%	3.07%	2.18%
Selling, General & Admin	6.52M	13.9M	54.01M	69.94M	114.94M
SG&A % of Revenue	-	-	7.08%	2.51%	1.92%
Research & Development	22.8M	18.81M	15.76M	15.49M	15.65M
R&D % of Revenue	-	-	2.07%	0.56%	0.26%
Other Operating Expenses	0	0	0	0	0
Operating Income+	-29.32M	-32.71M	-80.42M	-85.06M	-106.38M
Operating Margin %	-	-	-10.54%	-3.06%	-1.78%
Operating Income Growth %	-	-0.12%	-1.46%	-0.06%	-0.25%
EBITDA+	-28.84M	-32.29M	-75.57M	-73.5M	-98.41M
EBITDA Margin %	-	-	-9.9%	-2.64%	-1.65%
EBITDA Growth %	-	-0.12%	-1.34%	0.03%	-0.34%
D&A (Non-Cash Add-back)	478K	420K	4.86M	11.56M	7.97M
EBIT	-29.32M	-32.75M	-78.59M	-87.87M	-105.94M
Net Interest Income+	0	-1.17M	-5.63M	-6.23M	-4.54M
Interest Income	0	0	0	0	3.2M
Interest Expense	0	1.17M	5.63M	6.23M	7.73M
Other Income/Expense	0	-1.21M	-3.8M	-9.03M	-7.3M
Pretax Income+	-29.32M	-33.91M	-84.22M	-94.1M	-113.68M
Pretax Margin %	-	-	-11.04%	-3.38%	-1.9%
Income Tax+	148K	187K	15K	24K	135K
Effective Tax Rate %	1.01%	1.01%	1%	1%	1%
Net Income+	-29.47M	-34.1M	-84.24M	-94.12M	-113.81M
Net Margin %	-	-	-11.04%	-3.38%	-1.9%
Net Income Growth %	-	-0.16%	-1.47%	-0.12%	-0.21%
Net Income (Continuing)	-29.47M	-34.1M	-84.24M	-94.12M	-113.81M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.59	-0.69	-1.75	-2.04	-5.13
EPS Growth %	-	-0.17%	-1.54%	-0.17%	-1.51%
EPS (Basic)	-0.59	-0.69	-1.75	-2.04	-5.13
Diluted Shares Outstanding	49.53M	49.53M	49.53M	49.53M	49.53M
Basic Shares Outstanding	49.53M	49.53M	49.53M	49.53M	49.53M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Apr 2020	Apr 2021	Apr 2023	Apr 2024	Apr 2025
Total Current Assets+	6.17M	26.2M	18.42M	14.91M	255.33M
Cash & Short-Term Investments	5.76M	24.34M	14.81M	8.25M	237.59M
Cash Only	5.76M	24.34M	14.81M	8.25M	237.59M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	2.11M	2M	8.08M
Days Sales Outstanding	-	-	101.08	26.22	49.31
Inventory	0	0	2.11M	3.29M	6.57M
Days Inventory Outstanding	-	-	42.19	43.74	67.37
Other Current Assets	209K	1.34M	-1.74M	419K	1.69M
Total Non-Current Assets+	1.71M	4.33M	20.23M	31.04M	40.42M
Property, Plant & Equipment	1.13M	3.08M	16.72M	28.39M	36.91M
Fixed Asset Turnover	-	-	0.46x	0.98x	1.62x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	580K	1.24M	3.51M	2.65M	3.51M
Total Assets+	7.87M	30.52M	38.66M	45.95M	295.74M
Asset Turnover	-	-	0.20x	0.61x	0.20x
Asset Growth %	-	2.88%	0.27%	0.19%	5.44%
Total Current Liabilities+	4.02M	6.61M	36.74M	32.97M	37.98M
Accounts Payable	1.83M	1.7M	6.16M	23.89M	23.96M
Days Payables Outstanding	-	-	123.03	317.67	245.63
Short-Term Debt	0	0	20.45M	0	187K
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	0	0	4.67M	6.19M	8.49M
Current Ratio	1.54x	3.96x	0.50x	0.45x	6.72x
Quick Ratio	1.54x	3.96x	0.44x	0.35x	6.55x
Cash Conversion Cycle	-	-	20.24	-247.7	-128.95
Total Non-Current Liabilities+	0	22.15M	119.5M	222.35M	52.36M
Long-Term Debt	0	20.24M	17.32M	42.54M	41.1M
Capital Lease Obligations	0	1.55M	0	2.63M	3.03M
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	360K	102.17M	177.19M	8.24M
Total Liabilities	4.02M	28.76M	156.23M	255.33M	90.34M
Total Debt+	452K	22.85M	39.13M	45.17M	44.31M
Net Debt	-5.3M	-1.49M	24.32M	36.92M	-193.28M
Debt / Equity	0.12x	12.94x	-	-	0.22x
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-28.00x	-14.29x	-13.65x	-13.75x
Total Equity+	3.86M	1.77M	-117.58M	-209.38M	205.41M
Equity Growth %	-	-0.54%	-67.58%	-0.78%	1.98%
Book Value per Share	0.08	0.04	-2.37	-4.23	4.15
Total Shareholders' Equity	3.86M	1.77M	-117.58M	-209.38M	205.41M
Common Stock	1K	1K	1K	1K	51.35M
Retained Earnings	-135.98M	-170.08M	-312.31M	-406.44M	-520.25M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Apr 2020	Apr 2021	Apr 2023	Apr 2024	Apr 2025
Cash from Operations+	-30.29M	-29.89M	-69.64M	-72.23M	-77.61M
Operating CF Margin %	-	-	-9.13%	-2.6%	-1.3%
Operating CF Growth %	-	0.01%	-1.33%	-0.04%	-0.07%
Net Income	-29.47M	-34.1M	-84.24M	-94.12M	-113.81M
Depreciation & Amortization	478K	420K	4.86M	11.56M	7.97M
Stock-Based Compensation	0	1.86M	1.21M	1.49M	24.27M
Deferred Taxes	0	0	-45K	12K	64K
Other Non-Cash Items	706K	1.94M	7.28M	4.44M	10.11M
Working Capital Changes	-2.01M	-19K	1.3M	4.39M	-6.2M
Change in Receivables	0	0	0	-2M	-8.78M
Change in Inventory	0	0	-733K	-1.18M	-3.44M
Change in Payables	-790K	-132K	2.14M	7.34M	2.84M
Cash from Investing+	-232K	-334K	-15.46M	-12.23M	-23.31M
Capital Expenditures	-232K	-336K	-15.46M	-12.51M	-23.59M
CapEx % of Revenue	-	-	2.03%	0.45%	0.39%
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	2K	0	285K	283K
Cash from Financing+	30.24M	48.81M	96.11M	77.72M	330.26M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	-183K	-187K	-671K	-799K	-1.65M
Share Repurchases	-	-	-	-	-
Other Financing	30.42M	29M	0	-2.35M	12.73M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-30.52M	-30.23M	-85.1M	-84.75M	-101.2M
FCF Margin %	-	-	-11.15%	-3.05%	-1.69%
FCF Growth %	-	0.01%	-1.82%	0%	-0.19%
FCF per Share	-0.62	-0.61	-1.72	-1.71	-2.04
FCF Conversion (FCF/Net Income)	1.03x	0.88x	0.83x	0.77x	0.68x
Interest Paid	0	0	0	3.63M	0
Taxes Paid	70K	214K	12K	43K	0

Key Ratios

Metric	2020	2021	2023	2024	2025
Return on Equity (ROE)	-763.99%	-1212.91%	-	-	-55.41%
Return on Invested Capital (ROIC)	-	-8985.71%	-	-	-658.17%
Gross Margin	-	-	-139.59%	1.3%	40.47%
Net Margin	-	-	-1104.04%	-338.39%	-190.28%
Debt / Equity	0.12x	12.94x	-	-	0.22x
Interest Coverage	-	-28.00x	-14.29x	-13.65x	-13.75x
FCF Conversion	1.03x	0.88x	0.83x	0.77x	0.68x
Revenue Growth	-	-	-	264.53%	115.05%

Frequently Asked Questions

Growth & Financials

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported $74.3M in revenue for fiscal year 2025.

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) grew revenue by 115.1% over the past year. This is strong growth.

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported a net loss of $132.2M for fiscal year 2025.

Dividend & Returns

Yes, KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) pays a dividend with a yield of 0.15%. This makes it attractive for income-focused investors.

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has a return on equity (ROE) of -55.4%. Negative ROE indicates the company is unprofitable.

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) had negative free cash flow of $114.2M in fiscal year 2025, likely due to heavy capital investments.

← Back to Screener